home / stock / nvsef / nvsef short
Short Information | Novartis Ag Basel Akt (OTCMKTS:NVSEF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,743 |
Total Actual Volume | 123,304 |
Short Trends | |
---|---|
Cover Days | 15 |
Short Days | 4 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 137 |
Average Short Percentage | 25.88% |
Is there a NVSEF Short Squeeze or Breakout about to happen?
See the NVSEF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-26-2024 | $0 | $96 | $0 | $0 | 50 | 50 | 100% |
04-25-2024 | $0 | $96 | $0 | $0 | 16 | 16 | 100% |
04-23-2024 | $96.72 | $96 | $96.74 | $95.36 | 51,948 | 100 | 0.19% |
04-22-2024 | $95.27 | $95.11 | $95.27 | $95.11 | 492 | 98 | 19.92% |
04-19-2024 | $0 | $90.24 | $0 | $0 | 2 | 2 | 100% |
04-18-2024 | $90.24 | $90.24 | $90.24 | $90.24 | 10,985 | 54 | 0.49% |
04-17-2024 | $0 | $93.6375 | $0 | $0 | 97 | 10 | 10.31% |
04-16-2024 | $0 | $93.6375 | $0 | $0 | 10,592 | 3 | 0.03% |
04-15-2024 | $0 | $93.6375 | $0 | $0 | 133 | 2 | 1.5% |
04-12-2024 | $0 | $93.6375 | $0 | $0 | 46 | 1 | 2.17% |
04-10-2024 | $94.1 | $94.1 | $94.1 | $94.1 | 504 | 4 | 0.79% |
04-09-2024 | $95.7 | $95.7 | $95.7 | $95.7 | 1,698 | 1,654 | 97.41% |
04-02-2024 | $95 | $95 | $95 | $95 | 6,373 | 255 | 4% |
04-01-2024 | $0 | $96.51 | $0 | $0 | 56 | 20 | 35.71% |
03-25-2024 | $95.64 | $95.68 | $95.68 | $95.64 | 629 | 104 | 16.53% |
03-22-2024 | $0 | $96.39 | $0 | $0 | 877 | 17 | 1.94% |
03-14-2024 | $98.84 | $100 | $100 | $98.84 | 34,898 | 100 | 0.29% |
03-13-2024 | $98.1 | $98.1 | $98.1 | $98.1 | 503 | 31 | 6.16% |
03-12-2024 | $100.918 | $98.3221 | $100.918 | $98.3221 | 948 | 172 | 18.14% |
03-11-2024 | $99.47 | $98.7452 | $99.47 | $98.72 | 2,457 | 50 | 2.04% |
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...